Association between raised IL-8 serum levels and resistance to combined PEC-interferon + ribavirin therapy in HCV+ active chronic hepatitis;Associazione tra elevati livelli sierici di IL-8 e resistenza alla terapia combinata con PEG-interferon + ribavirina nell'epatite cronica attiva HCV+

Infezioni in Medicina

Volumn 16, Issue 2, 2008, Pages 80-85

  Cacopardo, Bruno ^a   Nigro, Luciano ^a   Nunnari, Giuseppe ^a   La Medica, Giuseppe ^a   Cappellani, Alessandro ^a   Palermo, Filippo ^a   Cappello, Elisa ^a   Russo, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Chronic hepatitis C; IL 8; Peg IFN; Ribavirin

Indexed keywords

INTERLEUKIN 8; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC ACTIVE HEPATITIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; NON INVASIVE MEASUREMENT; TH1 CELL; TH2 CELL; VIRUS RESISTANCE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-8; MALE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 47149101801     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Alter H.J. To C or not to C: these are the questions. Blood 85, 1681-1695, 1995.
2. McHutkinson J.G., Gordon S.C., Shiff E.R., et al. Interferonalfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492, 1998.
3. Lam N.P., Neumann A.U., Gretch D.R., et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26, 226-231, 1997.
4. Lindsay K.L., Trepo C., Heintges T., et al. A randomized, duble-blind trial comparing pegylated interferon alfa-2b 31to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395-403, 2001.
5. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alfa therapy. Science 282, 103-107, 1998.
6. Enomoto N., Sakuma I., Asahina Y., et al. Comparison of full length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96 (1), 224-230, 1995.
7. Witherell G.W., Beineke P. Statistical analysis of combined substitutions in non-structural 5A region of hepatitis C virus and interferon response. J. Med. Virol. 63, 8-16, 2001.
8. Gale M.J., Korth M.J., Tang N.M., et al. Evidence that Hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the non-structural 5A protein. Virology 230, 217-227, 1997.
9. Gale M.J., Blakely C.M., Kwieciszewski B., et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanism of kinase regulation. Mol. Cell Biol. 18, 5208-5218, 1998.
10. Polyak S.J., Khabar K.S., Paschal D.M., et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6095-6106, 2001.
11. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukine-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75, 6209-6211, 2001.
12. Koo B.C.A., Mc Poland P., Wagoner J.P., Kane O.J., Lohmann V., Polyak S.J. Relationships between Hepatitis C Virus replication and CXCL-8 production in vitro. J. Virol. 841, 7885-7893, 2006.
13. Bird G. Interleukin-8 in alcoholic liver disease. Acta Gastroenterol. Belgium 57, 255-259, 1994.
14. Shimoda K., Begum N.A., Shibuta K. et al. Interleukin-8 and MRH (SDF1-alfa/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. Hepatology 28(1), 108-115, 1998.
15. Neuman M.G., Benhamou J.P., Malkiewicz I.M., et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin. Biochem. 34, 173-182, 2001.
16. Blackard J.T., Kang M., Sherman K.E., Koziel M.J., Peters M.G., Chung R.T. Effects of HCV treatment on cytokine expression during HCV-HIV coinfection. J. Interferon Cytokine Res. 26, 834-838, 2006.
17. Zekri A.R.N., Haleem H.A, Esmat G.E-D. et al. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J. Viral Hepatitis 14, 468-477, 2007.